Walleye Capital’s AstraZeneca AZN Stock Holding History

Walleye Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$197	Sell	1 -217,697	-100%	-$42M	﹤0.01%	4287
2025 Q4	$40M	Buy	217,698 +9,305	+4%	+$1.63M	0.12%	95
2025 Q3	$32M	Buy	208,393 +20,626	+11%	+$3.12M	0.12%	122
2025 Q2	$26.2M	Buy	187,767 +11,995	+7%	+$1.68M	0.1%	155
2025 Q1	$25.8M	Sell	175,772 -6,468	-4%	-$936K	0.12%	146
2024 Q4	$23.9M	Sell	182,240 -54,251	-23%	-$7.6M	0.06%	275
2024 Q3	$36.9M	Buy	236,491 +49,348	+26%	+$7.97M	0.08%	167
2024 Q2	$29.2M	Buy	187,143 +56,621	+43%	+$8.52M	0.05%	234
2024 Q1	$17.7M	Sell	130,522 -12,440	-9%	-$1.65M	0.03%	485
2023 Q4	$19.3M	Sell	142,962 -40,083	-22%	-$5.21M	0.04%	345
2023 Q3	$24.8M	Buy	+183,045	New	+$25M	0.06%	190
2019 Q2	–	Sell	-327	Closed	-$26K	–	1725
2019 Q1	$26K	Buy	+327	New	+$25.8K	﹤0.01%	1316

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Walleye Capital's AZN Position: Q1 2026 in Review

Walleye Capital reduced its AstraZeneca (AZN) stake by 100% in Q1 2026, selling an estimated $42M and leaving 1 share worth $197. The position accounts for ﹤0.01% of the portfolio, ranked #4287.

Walleye Capital first reported a position in AZN in Q1 2019 and has held it in 12 quarters since. The position peaked at $40M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Walleye Capital held 1 share of AstraZeneca worth $197 as of Q1 2026.
Walleye Capital sold 217,697 AstraZeneca shares in Q1 2026, an estimated $42M.
AstraZeneca made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #4287 holding.
Walleye Capital first reported a position in AstraZeneca in Q1 2019 and has held it in 12 quarters since.
Walleye Capital's AstraZeneca position peaked at $40M in Q4 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.